Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data
暂无分享,去创建一个
[1] G. Pinkus,et al. The value of Wilms tumor susceptibility gene 1 in cytologic preparations as a marker for malignant mesothelioma , 2002, Cancer.
[2] M. Wick. Immunophenotyping of malignant mesothelioma. , 1997, The American journal of surgical pathology.
[3] P. Fetsch,et al. Hyaluronate binding probe and CD44 in the differential diagnosis of malignant effusions: Disappointing results in cytology material , 1998, Diagnostic cytopathology.
[4] C. Comin,et al. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. , 2001, Human pathology.
[5] A. Vortmeyer,et al. Immunocytochemical differential diagnosis of diffuse malignant pleural mesotheliomas--a clinicomorphological study of 158 cases. , 1991, Anticancer research.
[6] F. Hirsch,et al. Are pathologists biased by clinical information?: A blinded cross-over study of the histopathological diagnosis of mesothelial tumours versus pulmonary adenocarcinoma. , 1994, Lung cancer.
[7] Hector Battifora,et al. Tumors of the serosal membranes , 1995 .
[8] N. Ordóñez. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[9] S. Mills,et al. Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: a histochemical, ultrastructural, and immunohistologic study of 103 cases. , 1990, Human pathology.
[10] R. Attanoos,et al. Primary sarcomas of the lung: a clinicopathological and immunohistochemical study of 14 cases , 1996, Histopathology.
[11] J. Churg,et al. Histochemistry in the diagnosis of malignant mesothelioma. , 1973, Annals of clinical and laboratory science.
[12] J. Said,et al. Keratin in human lung tumors. Patterns of localization of different-molecular-weight keratin proteins. , 1983, The American journal of pathology.
[13] Leers,et al. E‐cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma , 1998, Histopathology.
[14] W. Kwee,et al. Histologic distinction between malignant mesothelioma, benign pleural lesion and carcinoma metastasis , 2004, Virchows Archiv A.
[15] H. Loosli,et al. Immunohistological study of malignant diffuse mesotheliomas of the pleura , 1984, Histopathology.
[16] M. Kaneko,et al. Blood group antigens, Lewisx and Lewisy in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma. , 1989, The American journal of pathology.
[17] A. Hjerpe,et al. An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma. , 2000, American journal of clinical pathology.
[18] I. Downie,et al. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies. , 2001, American journal of clinical pathology.
[19] J. Oates,et al. Anti‐cytokeratin 5/6: a positive marker for epithelioid mesothelioma , 1997, Histopathology.
[20] L. Weiss,et al. Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma. , 1992, Human pathology.
[21] G. Sterrett,et al. Detection of Tissue Cea‐Like Substance as an Aid in the Differential Diagnosis of Malignant Mesothelioma , 1982, Pathology.
[22] C. Otis,et al. Immunohistochemical Evaluation of Pleural Mesothelioma and Pulmonary Adenocarcinoma: A Bi-institutional Study of 47 Cases , 1987, The American journal of surgical pathology.
[23] S. Sahn. Malignancy metastatic to the pleura. , 1998, Clinics in chest medicine.
[24] H. Battifora,et al. Distinction of mesothelioma from adenocarcinoma. An immunohistochemical approach , 1985, Cancer.
[25] P. Cagle,et al. p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens. , 1994, Human pathology.
[26] R. Attanoos,et al. CD44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma , 1997, Histopathology.
[27] J. Bellocq,et al. [Malignant mesothelioma of the pleura. Analysis of its immunohistochemical aspects]. , 1990, Annales de pathologie.
[28] N. Ordóñez. The Immunohistochemical Diagnosis of Mesothelioma: Differentiation of Mesothelioma and Lung Adenocarcinoma , 1989, The American journal of surgical pathology.
[29] P. Betta,et al. Newly marketed tissue markers for malignant mesothelioma: immunoreactivity of rabbit AMAD-2 antiserum compared with monoclonal antibody HBME-1 and a review of the literature on so-called antimesothelioma antibodies. , 1997, Human pathology.
[30] P. Betta,et al. New marker for mesothelioma: an immunoperoxidase study. , 1986, Journal of clinical pathology.
[31] M. Pfaltz,et al. Immunohistochemistry in the diagnosis of malignant mesothelioma , 2004, Virchows Archiv A.
[32] W. Grigioni,et al. Immunohistochemical Panels For Differentiating Epithelial Malignant Mesothelioma From Lung Adenocarcinoma: A Study With Logistic Regression Analysis , 2001, The American journal of surgical pathology.
[33] M. Miettinen,et al. Expression of Calretinin, Thrombomodulin, Keratin 5, and Mesothelin in Lung Carcinomas of Different Types: An Immunohistochemical Analysis of 596 Tumors in Comparison With Epithelioid Mesotheliomas of the Pleura , 2003, The American journal of surgical pathology.
[34] B Terracini,et al. Malignant mesothelioma of the pleura: interobserver variability. , 1995, Journal of clinical pathology.
[35] N. Ordóñez,et al. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. , 2000, The American journal of surgical pathology.
[36] Klaus Kayser,et al. Glyco‐ and immunohistochemical refinement of the differential diagnosis between mesothelioma and metastatic carcinoma and survival analysis of patients , 2001, The Journal of pathology.
[37] V. Roggli,et al. Diagnosis of diffuse malignant mesothelioma: experience of a US/Canadian Mesothelioma Panel. , 1991, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[38] Y. Shimosato,et al. Histological Typing of Lung and Pleural Tumours , 1999, World Health Organization.
[39] P. Hasleton,et al. Immunohistochemistry and the diagnosis of malignant mesothelioma , 2001, Histopathology.
[40] S. Hirohashi,et al. Expression of Vimentin in Surgically Resected Adenocarcinomas and Large Cell Carcinomas of Lung , 1986, The American journal of surgical pathology.
[41] N. Ordóñez,et al. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. , 1998, The American journal of surgical pathology.
[42] A. Hjerpe,et al. Immunohistochemical reactivity in mesothelioma and adenocarcinoma: A stepwise logistic regression analysis , 1994, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[43] Phil Gold,et al. SPECIFIC CARCINOEMBRYONIC ANTIGENS OF THE HUMAN DIGESTIVE SYSTEM , 1965, The Journal of experimental medicine.
[44] N. Ordóñez,et al. Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. , 1992, The American journal of pathology.
[45] J. Peto,et al. Continuing increase in mesothelioma mortality in Britain , 1995, The Lancet.
[46] K. Gatter,et al. Immunohistological staining of reactive mesothelium, mesothelioma, and lung carcinoma with a panel of monoclonal antibodies. , 1987, Journal of clinical pathology.
[47] P. Majerus,et al. Thrombomodulin as a marker for vascular tumors. Comparative study with factor VIII and Ulex europaeus I lectin. , 1987, American journal of clinical pathology.
[48] Rogers. Spencer's pathology of the lung , 1999, Histopathology.
[49] F. Puglisi,et al. TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung. , 1998, Cancer letters.
[50] M. Jaurand,et al. The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas. , 1995, Human pathology.
[51] L. Happerfield,et al. The differential diagnosis of epithelial‐type mesothelioma from adenocarcinoma and reactive mesothelial proliferation , 1991, The Journal of pathology.
[52] K. Kerr,et al. HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura. , 1997, Journal of clinical pathology.
[53] A. Churg. Immunohistochemical staining for vimentin and keratin in malignant mesothelioma , 1985, The American journal of surgical pathology.
[54] K. Johnson,et al. Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues. , 1997, Human pathology.
[55] D. Allred,et al. Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas. , 2009, Archives of pathology & laboratory medicine.
[56] J. Whitsett,et al. Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. , 1999, Human pathology.
[57] N. Ordóñez. The Immunohistochemical Diagnosis of Mesothelioma: A Comparative Study of Epithelioid Mesothelioma and Lung Adenocarcinoma , 2003, The American journal of surgical pathology.
[58] S. Hirohashi,et al. Immunohistochemical distinction of malignant mesothelioma from pulmonary adenocarcinoma with anti-surfactant apoprotein, anti-Lewisa, and anti-Tn antibodies. , 1989, Human pathology.
[59] G. Viale,et al. Calretinin: a novel immunocytochemical marker for mesothelioma. , 1996, The American journal of surgical pathology.
[60] George L. Wright,et al. Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma , 1991, Cancer.
[61] A. Niezabitowski,et al. Calretinin and Other Mesothelioma Markers in Synovial Sarcoma: Analysis of Antigenic Similarities and Differences With Malignant Mesothelioma , 2001, The American journal of surgical pathology.
[62] H. Moch,et al. Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I: immunohistochemical findings , 2005, Virchows Archiv A.
[63] Edwards,et al. HBME‐1, MOC‐31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma , 2000, Histopathology.
[64] K. Müller,et al. [Immunohistochemical studies for the differential diagnosis of primary and secondary pleural tumors]. , 1986, Verhandlungen der Deutschen Gesellschaft fur Pathologie.
[65] V. Roggli,et al. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). , 1986, The American journal of pathology.
[66] J. Schlom,et al. Distinguishing malignant mesothelioma from pulmonary adenocarcinoma: An immunohistochemical approach using a panel of monoclonal antibodies , 1990, Journal of surgical oncology.
[67] J. Dahlstrom,et al. DISTINCTIVE MICROVILLOUS BRUSH BORDER STAINING WITH HBME‐1 DISTINGUISHES PLEURAL MESOTHELIOMAS FROM PULMONARY ADENOCARCINOMAS , 2001, Pathology.
[68] P. Lee,et al. Interpretation and Uses of Medical Statistics. , 1969 .
[69] T. H. van der Kwast,et al. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma , 1991, The Journal of pathology.
[70] P. Hasleton,et al. Immunoreactivity for cadherins, HGF/SF, met, and erbB‐2 in pleural malignant mesotheliomas , 2000, Histopathology.
[71] A. Churg,et al. Carcinoembryonic antigen and milk-fat globule protein staining of malignant mesothelioma and adenocarcinoma of the lung. , 1987, Archives of pathology & laboratory medicine.
[72] P. Hasleton,et al. Vimentin, carcinoembryonic antigen and keratin in the diagnosis of mesothelioma, adenocarcinoma and reactive pleural lesions. , 1990, The European respiratory journal.
[73] C. Kortsik,et al. Immunocytochemical characterization of malignant mesothelioma and carcinoma metastatic to the pleura: IOB3—A new tumor marker , 2008, Lung.
[74] J. Riera,et al. The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval. , 1997, The American journal of surgical pathology.
[75] B. Corrin,et al. Pleural mesothelioma of epithelial type and pulmonary adenocarcinoma: An ultrastructural and cytochemical comparison , 1987, The Journal of pathology.
[76] G. Pinkus,et al. Mesothelioma: profile of keratin proteins and carcinoembryonic antigen: an immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas. , 1982, The American journal of pathology.
[77] N. Ordóñez. The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies. , 1997, The American journal of surgical pathology.
[78] Z. Zakov,et al. Interpretation and Uses of Medical Statistics by Geoffrey J. Bourke, Leslie E. Daly, and James McGilvray , 1987 .
[79] P. Vogt,et al. The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type. , 1996, Pathology, research and practice.
[80] H. Battifora,et al. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen. , 1986, The American journal of pathology.
[81] H. Stein,et al. Ber-EP 4 : new monoclonal antibody which distinguishes epithelia from mesothelia , 2022 .
[82] R. Stahel,et al. Monoclonal antibodies against mesothelial membrane antigen discriminate between malignant mesothelioma and lung adenocarcinoma , 1988, International journal of cancer.
[83] P. Chu,et al. Expression of Cytokeratin 5/6 in Epithelial Neoplasms: An Immunohistochemical Study of 509 Cases , 2002, Modern Pathology.
[84] B. Jasani,et al. Comparison of tumour markers in malignant mesothelioma and pulmonary adenocarcinoma. , 1985, Thorax.
[85] Mayordomo,et al. A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours , 1998, Histopathology.
[86] C. Meijer,et al. Simultaneous immunoenzyme staining of vimentin and cytokeratins with monoclonal antibodies as an aid in the differential diagnosis of malignant mesothelioma from pulmonary adenocarcinoma , 1986, Virchows Archiv. B, Cell pathology including molecular pathology.
[87] M. Jaurand,et al. The Mesothelial Cell and Mesothelioma , 1994 .
[88] T. Kawai,et al. Lectin histochemistry of normal lung and pulmonary adenocarcinoma. , 1988, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[89] J. Morris,et al. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. , 1995, The American journal of pathology.
[90] J. Legier,et al. Immunohistochemical diagnosis of mesothelioma , 1994 .
[91] A. Nicholson,et al. Value of the Mesothelium-Associated Antibodies Thrombomodulin, Cytokeratin 5/6, Calretinin, and CD44H in Distinguishing Epithelioid Pleural Mesothelioma from Adenocarcinoma Metastatic to the Pleura , 2000, Modern Pathology.
[92] S. Paulsen,et al. The value of immunohistochemistry of pleural biopsy specimens in the differential diagnosis between malignant mesothelioma and metastatic carcinoma. , 1994, Pathology, research and practice.
[93] R. Attanoos,et al. Mesothelioma‐binding antibodies: thrombomodulin, OV 632 and HBME‐1 and their use in the diagnosis of malignant mesothelioma , 1996, Histopathology.
[94] H. Hoogsteden,et al. The influence of the diagnostic technique on the histopathological diagnosis in malignant mesothelioma , 1991, Virchows Archiv A.
[95] D. Allred,et al. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. , 1993, Human pathology.
[96] M. Gaffey,et al. Immunoreactivity for BER‐EP4 in Adenocarcinomas, Adenomatoid Tumors, and Malignant Mesotheliomas , 1992, The American journal of surgical pathology.
[97] L. Weiss,et al. Ber‐EP4 Antibody as a Discriminant in the Differential Diagnosis of Malignant Mesothelioma Versus Adenocarcinoma , 1991, The American journal of surgical pathology.
[98] A. Thor,et al. Differentiation of adenocarcinoma of the lung from mesothelioma. Periodic acid-Schiff, monoclonal antibodies B72.3, and Leu M1. , 1988, The American journal of pathology.
[99] A. Hjerpe,et al. Carcinoembryonic antigen-like reactivity in malignant mesothelioma. A comparison between different commercially available antibodies. , 1994, Cancer.
[100] J. Bellocq,et al. [Immunohistochemistry in the differential diagnosis of mesothelioma and adenocarcinoma. Evaluation of 5 new antibodies and 6 traditional antibodies]. , 1998, Annales de pathologie.
[101] E. van Marck,et al. WT1 MUTATION IN MALIGNANT MESOTHELIOMA AND WT1 IMMUNOREACTIVITY IN RELATION TO p53 AND GROWTH FACTOR RECEPTOR EXPRESSION, CELL‐TYPE TRANSITION, AND PROGNOSIS , 1997, The Journal of pathology.
[102] P. Gold,et al. Absence of carcinoembryonic antigen‐like material in mesothelioma An immunohistochemical differentiation from other lung cancers , 1979, Cancer.
[103] B. D. De Young,et al. Anti-MOC-31: a potential addition to the pulmonary adenocarcinoma versus mesothelioma immunohistochemistry panel. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[104] D. Henderson,et al. Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review. , 1998, American journal of clinical pathology.
[105] G. Chejfec,et al. Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12. , 1986, The American journal of pathology.
[106] C. Esmon,et al. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. , 1982, The Journal of biological chemistry.
[107] B. Jasani,et al. The use of vimentin antibodies in the diagnosis of malignant mesothelioma , 2004, Virchows Archiv A.
[108] B. Addis,et al. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies , 2002, Journal of clinical pathology.
[109] H. Battifora,et al. Leu-Ml Antigen in Human Neoplasms: An Immunohistologic Study of 400 Cases , 1986, The American journal of surgical pathology.
[110] N. Ordóñez,et al. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. , 1998, Human pathology.
[111] S. Tuttle,et al. Diagnostic histochemical and immunohistochemical studies in malignant mesothelioma , 1987, Journal of surgical oncology.
[112] A. Churg,et al. Immunohistochemical staining for keratin and carcinoembryonic antigen in the diagnosis of malignant mesothelioma , 1984, The American journal of surgical pathology.
[113] G. Pinkus,et al. ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies. , 1990, The American journal of pathology.
[114] H. Stein,et al. Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelial. , 1990, Journal of clinical pathology.
[115] D. Jones,et al. Use of antibodies to carcinoembryonic antigen and human milk fat globule to distinguish carcinoma, mesothelioma, and reactive mesothelium. , 1984, Journal of clinical pathology.
[116] J. Oates,et al. OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed and paraffin wax embedded material. , 1995, Journal of clinical pathology.
[117] Gregory B. Jobes,et al. Differential expression of CD44S and hyaluronic acid in malignant mesotheliomas, adenocarcinomas, and reactive mesothelial hyperplasias , 1998 .